October 03, 2018

PHARMACOKINETIC PROFILE OF TROGARZOTM PRESENTED AT IDWEEK

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that pharmacokinetic data from the pivotal phase III clinical trial for TrogarzoTM (ibalizumab-uiyk) injection will be presented tomorrow at IDWeekTM in San Francisco.